Medicina
Departamento
Centre Hospitalier Universitaire de Liège
Lieja, BélgicaPublicaciones en colaboración con investigadores/as de Centre Hospitalier Universitaire de Liège (73)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
European urology, Vol. 83, Núm. 3, pp. 200-209
-
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
European Urology, Vol. 84, Núm. 3, pp. 321-330
-
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1759-1770.e7
2022
-
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
npj Breast Cancer, Vol. 8, Núm. 1
-
Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 710.e1-710.e10
-
Erratum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study (Oncotarget (2020) 11 (2172-2181) DOI: 10.18632/oncotarget.27612)
Oncotarget
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
-
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64
2021
-
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)
Annals of Oncology
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
-
Multinational evaluation of the BioFire® FilmArray® Pneumonia plus Panel as compared to standard of care testing
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 8, pp. 1609-1622
-
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024
-
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
Respiratory Medicine, Vol. 178
-
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
European heart journal, Vol. 42, Núm. 6, pp. 657-670
-
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2
2020
-
Characteristics and treatment regimens across ERS SHARP severe asthma registries
European Respiratory Journal, Vol. 55, Núm. 1
-
Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association
European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 1, pp. 76-89
-
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1857-1866